A very high percentage of Prior Authorization (PA) requests are approved…but about 40% of these prescriptions are abandoned during the PA process, around 74.4 million prescriptions a year.
The good news … is that innovation is addressing diseases with high-unmet need such as oncology, autoimmune diseases, and central nervous system (CNS) disorders. But, there is a complicating factor in the economic story: the patient population benefiting from launch brands is becoming smaller.
ZS oncology experts Christina Corridon and Pavan Anne discuss their recent survey of physicians, payers, and pharmacy managers regarding attitudes toward biosimilars
Most health plans are covering at least one of the two biosimilar products currently on the market, according to new research by the strategic advisory company Avalere.
What are key trends in the transparency compliance landscape?
Many a blog, article, and cover story has focused on the impact (current and future) of healthcare reform. But some interesting healthcare industry changes have been occurring simultaneously with, and are very much accelerated by, the impact of reform. One of these important market changes is the shift from traditional silos of key customer decision-making to a more blended approach to healthcare (and formulary) decision-making.